-
公开(公告)号：WO2008094556A2
公开(公告)日：2008-08-07
申请号：PCT/US2008/001172
申请日：2008-01-30
Applicant: BIOGEN IDEC MA INC. , GUCKIAN, Kevin , LEE, Wen-cherng , LIN, Edward (Ted)
Inventor： GUCKIAN, Kevin , LEE, Wen-cherng , LIN, Edward (Ted)
IPC: C07D471/04 , A61K31/437 , A61P35/00
CPC classification number: C07D471/04
Abstract: In one aspect, the invention features a compound of the general Formula (I). Compounds of Formula (I) possess high affinity for Alk 5 and/or AIk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders.
Abstract translation: 一方面，本发明的特征在于通式（I）的化合物。 式（I）的化合物对Alk 5和/或AIk 4具有高亲和力，并且可用作其拮抗剂，用于预防和/或治疗包括纤维化病症在内的许多疾病。
-
2.发明申请INDAZOLE DERIVATIVES AS MODULATORS OF INTERLEUKIN- 1 RECEPTOR-ASSOCIATED KINASE 审中-公开作为INTERLEUKIN-1受体相关激酶调节剂的吲哚衍生物
公开(公告)号：WO2008030584A3
公开(公告)日：2008-07-17
申请号：PCT/US2007019588
申请日：2007-09-07
Applicant: BIOGEN IDEC INC , GUCKIAN KEVIN , JEWELL CHARLES , CONLAN PATRICK , LIN EDWARD YIN-SHIANG , CHAN TIMOTHY
Inventor： GUCKIAN KEVIN , JEWELL CHARLES , CONLAN PATRICK , LIN EDWARD YIN-SHIANG , CHAN TIMOTHY
IPC: C07D401/14 , A61K31/4164 , A61K31/44 , A61P3/00 , A61P29/00 , A61P35/00 , C07D403/12 , C07D403/14
CPC classification number: C07D403/12 , C07D401/14 , C07D403/14
Abstract: The present invention relates to modulators of IRAK kinases of formula (I) and provides compositions comprising such modulators, as well as methods therewith for treating IRAK- mediated or IRAK -associated conditions or diseases.
Abstract translation: 本发明涉及式（I）的IRAK激酶的调节剂，并提供包含这种调节剂的组合物，以及其用于治疗IRAK介导的或与IRAK相关的病症或疾病的方法。
-
公开(公告)号：WO2010051030A1
公开(公告)日：2010-05-06
申请号：PCT/US2009/005897
申请日：2009-10-30
Applicant: BIOGEN IDEC MA INC. , GUCKIAN, Kevin, M. , CALDWELL, Richard, D. , KUMARAVEL, Gnanasambandam , LEE, Wen-cherng , LIN, Edward, Yin-shiang , LIU, Xiaogao , MA, Bin , SCOTT, Daniel, M. , SHI, Zhan , ZHENG, Guo, Zhu , TAVERAS, Arthur, G. , THOMAS, Jermaine
Inventor： GUCKIAN, Kevin, M. , CALDWELL, Richard, D. , KUMARAVEL, Gnanasambandam , LEE, Wen-cherng , LIN, Edward, Yin-shiang , LIU, Xiaogao , MA, Bin , SCOTT, Daniel, M. , SHI, Zhan , ZHENG, Guo, Zhu , TAVERAS, Arthur, G. , THOMAS, Jermaine
IPC: A01N47/10 , A61K31/27 , A61K31/135
CPC classification number: A61K31/135 , A61K31/27 , C07C205/26 , C07C205/50 , C07C217/52 , C07C217/60 , C07C229/32 , C07C271/16 , C07D263/38 , C07F9/091 , C07F9/093 , C07F9/653 , C07F9/65744
Abstract: Compounds that have agonist activity at one or more of the SlP receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S lP receptors.
Abstract translation: 提供了在一种或多种S1P受体上具有激动剂活性的化合物。 这些化合物是鞘氨醇类似物，其在磷酸化之后可以作为S1P受体的激动剂。
-
公开(公告)号：WO2007059359A3
公开(公告)日：2007-05-24
申请号：PCT/US2006/045095
申请日：2006-11-21
Applicant: BIOGEN IDEC MA INC. , LEE, Wen-Cherng , CARTER, Mary, Beth , CHUAQUI, Claudio , GUCKIAN, Kevin , LIN, Edward, Yin-shiang , CHOI, Michael, J. , DENG, Zhan , BORIACK-SJODIN, Paula, Ann , SUN, Lihong
Inventor： LEE, Wen-Cherng , CARTER, Mary, Beth , CHUAQUI, Claudio , GUCKIAN, Kevin , LIN, Edward, Yin-shiang , CHOI, Michael, J. , DENG, Zhan , BORIACK-SJODIN, Paula, Ann , SUN, Lihong
IPC: C07D401/14 , C07D403/04 , C07D413/14 , C07D417/04 , C07D417/14 , C07D419/14 , A61K31/4184 , A61P35/00
Abstract: The invention is related to compounds of formula (I) as antagonists of the TGFβ family type I receptors, Alk5 and/or AIk 4, compositions and methods of use. The compounds of formula (I) can be employed in the prevention and/or treatment of diseases such as fibrosis (e.g., renal fibrosis, pulmonary fibrosis, and hepatic fibrosis), progressive cancers, or other diseases for which reduction of TGFβ family signaling activity is desirable.
-
5.发明申请IMIDAZOLONE COMPOUNDS AS TGF-BETA FAMILY TYPE I RECEPTORS, ALK5 AND/OR ALK4 ANTAGONISTS 审中-公开作为TGF-β家族I型受体的IMIDAZOLONE化合物，ALK5和/或ALK4拮抗剂
公开(公告)号：WO2008094556A3
公开(公告)日：2008-09-25
申请号：PCT/US2008001172
申请日：2008-01-30
Applicant: BIOGEN IDEC INC , GUCKIAN KEVIN , LEE WEN-CHERNG , LIN EDWARD TED
Inventor： GUCKIAN KEVIN , LEE WEN-CHERNG , LIN EDWARD TED
IPC: C07D471/04 , A61K31/437 , A61P35/00
CPC classification number: C07D471/04
Abstract: In one aspect, the invention features a compound of the general Formula: (I); wherein R 2 is aryl or heteroaryl and R 1 is heteroaryl Compounds of Formula (I) possess high affinity for Alk 5 and/or AIk 4, and can be useful as antagonists thereof for preventing and/or treating fibrotic disorders or progressive cancers.
Abstract translation: 一方面，本发明的特征在于通式（I）的化合物： 其中R 2是芳基或杂芳基，R 1是杂芳基式（I）的化合物对Alk 5和/或Alk 4具有高亲和力，并且可用作拮抗剂 用于预防和/或治疗纤维化疾病或进行性癌症。
-
Patent Agency Ranking
公开(公告)号：WO2008005457A3
公开(公告)日：2008-07-24
申请号：PCT/US2007015397
申请日：2007-07-02
Applicant: SUNESIS PHARMACEUTICALS , BIOGEN IDEC INC , LIND KENNETH EGNARD , CAO KATHY , LIN EDWARD YIN-SHIANG , NGUYEN THINH BA , TANGONAN BRADLEY T , ERLANSON DANIEL A , GUCKIAN KEVIN , SIMMONS ROBERT LOWELL , LEE WEN-CHERNG , SUN LIHONG , HANSEN STIG , PATHAN NUZHAT , ZHANG LEI
Inventor： LIND KENNETH EGNARD , CAO KATHY , LIN EDWARD YIN-SHIANG , NGUYEN THINH BA , TANGONAN BRADLEY T , ERLANSON DANIEL A , GUCKIAN KEVIN , SIMMONS ROBERT LOWELL , LEE WEN-CHERNG , SUN LIHONG , HANSEN STIG , PATHAN NUZHAT , ZHANG LEI
IPC: C07D401/12
CPC classification number: C07D471/04 , A61K31/4412 , A61K31/443 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/4985 , A61K31/506 , A61K31/519 , A61K31/5377 , C07D211/86 , C07D213/64 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D407/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D487/04
Abstract: The present invention provides pyridinonyl PDKl inhibitors and methods of treating cancer using the same.
Abstract translation: 本发明提供吡啶基PDK1抑制剂和使用其治疗癌症的方法。
-
公开(公告)号：WO2008030584A2
公开(公告)日：2008-03-13
申请号：PCT/US2007/019588
申请日：2007-09-07
Applicant: BIOGEN IDEC MA INC. , GUCKIAN, Kevin , JEWELL, Charles , CONLAN, Patrick , LIN, Edward, Yin-Shiang , CHAN, Timothy
Inventor： GUCKIAN, Kevin , JEWELL, Charles , CONLAN, Patrick , LIN, Edward, Yin-Shiang , CHAN, Timothy
CPC classification number: C07D403/12 , C07D401/14 , C07D403/14
Abstract: The present invention relates to modulators of IRAK kinases and provides compositions comprising such modulators, as well as methods therewith for treating IRAK- mediated or IRAK-associated conditions or diseases.
Abstract translation: 本发明涉及IRAK激酶的调节剂并提供包含这种调节剂的组合物，以及其用于治疗IRAK介导的或与IRAK相关的病症或疾病的方法。
-
公开(公告)号：WO2012109108A1
公开(公告)日：2012-08-16
申请号：PCT/US2012/023799
申请日：2012-02-03
Applicant: BIOGEN IDEC MA INC. , THOMAS, Jermaine , MI, Sha , LIN, Edward, Yin-shiang , ZHENG, Guo, Zhu , MA, Bin , CALDWELL, Richard, D. , GUCKIAN, Kevin , KUMARAVEL, Gnanasambandam
Inventor： THOMAS, Jermaine , MI, Sha , LIN, Edward, Yin-shiang , ZHENG, Guo, Zhu , MA, Bin , CALDWELL, Richard, D. , GUCKIAN, Kevin , KUMARAVEL, Gnanasambandam
IPC: A01N43/40 , A61K31/445
CPC classification number: A61K31/445 , A61K31/225 , A61K31/4545 , A61K31/4709 , A61K31/498 , A61K31/517 , A61K31/55 , A61K31/695 , A61K38/21 , A61K39/3955 , C07D211/34 , C07D211/60 , C07D211/62 , C07D215/20 , C07D401/06 , C07D405/12 , C07K16/2842
Abstract: Compounds of formula (I) or (II) can modulate the activity of SIP receptors.
Abstract translation: 式（I）或（II）的化合物可以调节SIP受体的活性。
-
公开(公告)号：WO2011044157A1
公开(公告)日：2011-04-14
申请号：PCT/US2010/051517
申请日：2010-10-05
Applicant: BIOGEN IDEC MA INC. , SUNESIS PHARMACEUTICALS, INC. , ARNDT, Joseph , CHAN, Timothy , GUCKIAN, Kevin , KUMARAVEL, Gnanasambandam , LEE, Wen-Cherng , LIN, Edward, Yin-shiang , SCOTT, Daniel , SUN, Lihong , THOMAS, Jermaine , VAN VLOTEN, Kurt , WANG, Deping , ZHANG, Lei , ERLANSON, Daniel
Inventor： ARNDT, Joseph , CHAN, Timothy , GUCKIAN, Kevin , KUMARAVEL, Gnanasambandam , LEE, Wen-Cherng , LIN, Edward, Yin-shiang , SCOTT, Daniel , SUN, Lihong , THOMAS, Jermaine , VAN VLOTEN, Kurt , WANG, Deping , ZHANG, Lei , ERLANSON, Daniel
IPC: A61K31/50
CPC classification number: C07D471/04 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/452 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/4985 , A61K31/517 , A61K31/519 , A61K31/53 , A61K31/5377 , A61K31/5383 , C07D213/82 , C07D213/85 , C07D241/26 , C07D241/28 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/04 , C07D409/14 , C07D417/14 , C07D473/34 , C07D487/04 , C07D491/052 , C07D498/04 , C07D519/00
Abstract: The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.
Abstract translation: 本发明提供可用作PDK1抑制剂的化合物。 本发明还提供了其组合物，以及治疗PDK1介导的疾病的方法。
-
公开(公告)号：WO2011017561A1
公开(公告)日：2011-02-10
申请号：PCT/US2010/044607
申请日：2010-08-05
Applicant: BIOGEN IDEC MA INC. , THOMAS, Jermaine , LIU, Xiaogao , LIN, Edward, Yin-Shiang , ZHENG, Guo, Zhu , MA, Bin , CALDWELL, Richard, D. , GUCKIAN, Kevin, M. , KUMARAVEL, Gnanasambandam , TAVERAS, Arthur, G.
Inventor： THOMAS, Jermaine , LIU, Xiaogao , LIN, Edward, Yin-Shiang , ZHENG, Guo, Zhu , MA, Bin , CALDWELL, Richard, D. , GUCKIAN, Kevin, M. , KUMARAVEL, Gnanasambandam , TAVERAS, Arthur, G.
IPC: A01N43/42
CPC classification number: A61K31/695 , A61K31/085 , A61K31/11 , A61K31/137 , A61K31/165 , A61K31/18 , A61K31/185 , A61K31/197 , A61K31/198 , A61K31/216 , A61K31/222 , A61K31/223 , A61K31/235 , A61K31/277 , A61K31/337 , A61K31/397 , A61K31/40 , A61K31/401 , A61K31/404 , A61K31/41 , A61K31/428 , A61K31/445 , A61K31/47 , A61K31/4709 , A61K31/472 , A61K31/517 , A61K31/662 , A61K31/683 , A61K45/06 , C07C43/247 , C07C47/575 , C07C229/14 , C07C229/22 , C07C229/46 , C07C229/48 , C07C237/08 , C07C237/52 , C07C255/54 , C07C309/14 , C07C311/51 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07D205/04 , C07D207/16 , C07D209/08 , C07D211/60 , C07D211/62 , C07D215/20 , C07D215/227 , C07D217/04 , C07D217/24 , C07D239/74 , C07D257/04 , C07D277/64 , C07D305/08 , C07D401/06 , C07D403/06 , C07D417/06 , C07F7/081 , C07F9/3808 , C07F9/3834 , C07F9/4006
Abstract: Compounds that have agonist activity at one or more of the SlP receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at SlP receptors.
Abstract translation: 提供了在一种或多种S1P受体上具有激动剂活性的化合物。 化合物是鞘氨醇类似物，其在磷酸化之后可以作为S1P受体的激动剂。
-
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.025 seconds)
